- Previous Close
2.3500 - Open
4.1000 - Bid --
- Ask --
- Day's Range
2.4100 - 7.5000 - 52 Week Range
1.0400 - 58.2000 - Volume
145,824,989 - Avg. Volume
981,225 - Market Cap (intraday)
20.995M - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-7.3000 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.00
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
bioviepharma.com14
Full Time Employees
June 30
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: BIVI
View More
Performance Overview: BIVI
Trailing total returns as of 2024-10-21, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIVI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIVI
View MoreValuation Measures
Market Cap
18.76M
Enterprise Value
1.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.21
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-66.69%
Return on Equity (ttm)
-208.26%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-33.01M
Diluted EPS (ttm)
-7.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
23.84M
Total Debt/Equity (mrq)
39.41%
Levered Free Cash Flow (ttm)
-18.78M